Stratégie de portefeuille et JUB : où se loge la valeur des actifs life sciences

Back from the BIO International Convention in San Diego, one observation stands out: the life sciences market is no longer discovering the Unified Patent Court (UPC), it is redefining it. The Court is no longer perceived as a mere dispute resolution forum, but as a mechanism that converts the territorial power of patents into economic value.

The conceptual tension lies there: a judicial institution, designed to settle disputes, now produces its most significant effects outside any litigation. Its legal effect remains adjudicative; its commercial effect has become transactional. The value of a life sciences patent portfolio is now formed in the light of what a single court might say about it.

For biotechs raising funds, licensees, acquirers and their advisers, this shift requires rethinking due diligence, contract drafting and portfolio governance.

The economics of a load-bearing floor

The protection structure has not changed: European patents, unitary patentsand supplementary protection certificates stack up as so many layers. What has changed is the economic performance of one of those layers. UPC decisions now extend across eighteen Contracting Member States: a single injunction covers most of the European market.

The counterpart is a centralised vulnerability: a patent can be revoked, in a single forum, for the entire territory. Arevocation action before the UPC concentrates into one set of proceedings what yesterday required a multinational campaign. The floor bears more weight, but it can give way in one piece. For an acquirer or an investor, that single point of failure is no longer an abstraction: it can be priced, hedged and negotiated.

Diligence as price formation

Legal uncertainty has become communicable and traceable. The due diligence question is no longer "in which jurisdictions do we need opinions?", but "how would this portfolio perform before a single Court whose measures, evidentiary powers and damages framework reshape the economics of litigation?".

The answer feeds directly into the price. A weak UPC profile, uncertain title, vulnerable claims, inconsistent opt-outs, depresses valuation; a solid profile supports it. Patent valuation now incorporates an anticipated litigation component, before any writ is served. What used to be a qualitative caveat buried in a diligence report has become a quantifiable input in the financial model.

UPC-readiness as a discipline

UPC-readiness is not a slogan but a verifiable discipline: a clean chain of title, secured priorities, defensible claim construction, sufficiency, novelty and inventive step tested under pressure, usable infringement evidence, clarity on licensees' rights, synchronisation of SPCs and regulatory timelines. None of these items is new in itself; what is new is that a single court can now test them all at once, and that counterparties know it.

Theopt-out illustrates the logic: it is no longer an administrative formality but a recorded financial decision. Leaving the system preserves national fragmentation and removes the risk of centralised revocation; staying in, or coming back, opens up pan-European enforcement. Each option has a price, which counterparties now know how to read.

Case law read as valuation

The first life sciences decisions supply the grammar of this diligence. NanoString v. 10x Genomics (UPC_CoA_335/2023, 26 February 2024) showed that provisional measures depend on the Court's own assessment of validity and claim scope: the intrinsic quality of the title commands the remedy.

The Amgen/Sanofi sequence is the purest example of a valuation event: revocation of the PCSK9 patent by the Munich Central Division on 16 July 2024, analysed in our article on the first revocation action before the UPC, then reversal by the Court of Appeal on 25 November 2025 (UPC_CoA_529/2024). In sixteen months, the same family went from impairment to leverage, along a procedural path observable by any investor in the Court's register of decisions.

The Düsseldorf decision in Sanofi/Regeneron v. Amgen (13 May 2025) completes the picture on the infringement side: for second medical use claims, infringement is not inferred from the molecule but from a structured inquiry into use, marketing and user perception. All parameters that serious due diligence must model, in line with the UPC's strategic lessons for life sciences.

Drafting around the Court

Representations and warranties must now cover the jurisdictional posture before the UPC: opt-out history, validity weak points, exposure to oppositions before theEPO, SPC dependencies, licensees' rights, evidence preservation.

Covenants follow the same slope: who may bring an action before the Court, who may settle it, who bears the revocation risk, who controls claim limitation, how milestone payments react to a narrowing of the title. The sequencing of proceedings, infringement, standalone revocation, counterclaims, itself becomes a negotiated clause, because it shifts the balance of the negotiation.

Large portfolios, a single forum: where value is set

Portfolios born of AI-assisted discovery grow fast and often rest on platform claims. A single forum simplifies their European enforcement profile: for a biotech, portfolio management becomes an exercise in continuous valuation, where questions of Court exposure, opt-outs and availability of the title arise before every funding round. The issue is no longer whether each patent would survive scrutiny in isolation, but how the portfolio behaves as a system before a single bench.

The central question is therefore no longer "would we prevail before the UPC?", but "what is this portfolio worth to an acquirer, a licensee, an investor who will ask that question?". That question is settled in the negotiation room, well before the courtroom, and sometimes in the shadow of an immediate enforcement risk we have described in relation to imminent infringement before the UPC. The UPC is not only the place where value is defended: it has become the place where value is set.

Key takeaways

• The UPC now produces its most significant effects outside litigation: it converts the territorial power of patents into transactional value, across eighteen Contracting States.
• Centralisation cuts both ways: pan-European enforcement through a single order, but a single revocation risk for the whole territory.
• Life sciences due diligence now includes a "UPC profile": title, claims, opt-outs, SPCs and evidence, translated directly into price.
• The Amgen sequence, revocation on 16 July 2024 then reversal on 25 November 2025, illustrates the magnitude of the valuation events the Court creates.
• Representations, warranties and covenants must now address the UPC posture: standing to sue, control of limitations, allocation of revocation risk, sequencing of proceedings.
• The opt-out is a recorded financial decision, not a formality: each option has a price that counterparties can read.

Frequently asked questions

Why does the UPC influence portfolio value before any litigation?

Because its decisions cover eighteen States and its framework of measures, evidence and damages is now predictable: counterparties price in how the portfolio would perform before it.

What is a solid UPC profile in due diligence?

A clean chain of title, claims defensible under strict construction, opt-outs consistent with the strategy, SPCs synchronised with regulatory timelines and usable infringement evidence.

Should life sciences patents be opted out?

There is no uniform answer: the opt-out removes the risk of centralised revocation but forgoes pan-European enforcement; the decision is taken patent by patent, according to the asset's value, its exposure and planned transactions.

How should licence agreements deal with the UPC?

By stipulating who may sue before the Court and settle, who bears the revocation risk, who controls claim limitation, and how milestone payments react to a narrowing of the title.

Dhenne Avocats advises life sciences companies on preparing their portfolios for the Unified Patent Court, pre-transaction audits and the associated litigation strategy. Talk to us.

This article is an original and substantially updated adaptation of an analysis by Matthieu Dhenne first published on Kluwer Patent Blog on July 9, 2026: Life Sciences Monetization After San Diego: The UPC as Portfolio Strategy.